Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0050 • ACR Convergence 2025
TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Preeyam Patel¹, Matthew Siegel², Emily Lewis³, David Giles³, Justin LaFountaine³, Joshua Friedman³ and Andy Spencer³, ¹Spyre Therapeutics, Waltham, ²Spyre Therapeutics, Menlo Park, CA, ³Spyre Therapeutics, Waltham, MA
Background/Purpose: The development of disease-modifying anti-rheumatic drugs (DMARDs) has reduced disease activity in patients living with rheumatic diseases. Despite this, there is continued unmet need…
Abstract Number: 2664 • ACR Convergence 2025
Neutrophil-to-Lymphocyte Ratio (NLR) as a Clinically Accessible Marker for Interferon Signatures in Autoimmune Diseases
YOSHINOBU KOYAMA¹, KENTA SHIDAHARA², YU NAKAI², YOSHIHARU SATO³ and YOSHINORI NISHIURA², ¹Japanese Red Cross Okayama Hospital, Okayama, Okayama, Japan, ²Japan Red Cross Okayama Hospital, Okayama-shi, Okayama, Japan, ³DNA Chip Research Inc., Kawasaki-shi, Kanagawa, Japan
Background/Purpose: Interferons (IFNs) play critical roles in systemic autoimmune diseases, particularly systemic lupus erythematosus (SLE), where heightened type I IFN signaling is a hallmark. Elevated…
Abstract Number: 2569 • ACR Convergence 2025
Performance of the PREVENT Heart Failure General Population Risk Score in Patients with Rheumatoid Arthritis
Ilana Usiskin¹, Katherine Zhong², Ying Qi³, Lauren rusnak¹, Andrew Cagan¹, Yumeko Kawano¹, Tianrun Cai¹, Daniel Solomon⁴, Jennifer Ho⁵, Brittany Weber⁶ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Short Hills, NJ, ³Brigham and Women’s Hospital, Boston, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of heart failure (HF) compared to the general population, and HF with preserved ejection fraction…
Abstract Number: 2280 • ACR Convergence 2025
Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis
Athanasios Mavropoulos¹, Christos Liaskos², Ioannis Alexiou³, Christina Katsiari⁴, Dimitrios Bogdanos⁵ and Lazaros Sakkas⁶, ¹University of Thessaly, Volos, Greece, ²University of Thessaly, Faculty of Medicine, Larisa, Greece, ³University General Hospital of larissa, Larissa, Greece, ⁴University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, ⁵Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece, ⁶Department of Rheumatology, University of Thessaly, Larissa, Greece
Background/Purpose: Abatacept, an efficacious therapy for rheumatoid arthritis (RA), inhibits the interaction between CD28 on T cells and CD80/CD86 on antigen-presenting cells (APCs). The aim…
Abstract Number: 2262 • ACR Convergence 2025
Assessment of small airway disease in rheumatoid arthritis
Stéphane HILLIQUIN¹, Huy-Thong HUA², Hà Pham-Ngoc², Frédérique Aubourg², Nhât-Nam Lê-Dông², Sven Günther³, Nicolas ROCHE⁴, Jérôme AVOUAC⁵, Yannick Allanore⁶ and Anh-Tuan Dinh-Xuan², ¹Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, ²Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, ³Unité exploration fonctionnelle respiratoire, Georges-Pompidou Hospital, APHP, PARIS, France, ⁴Pneumology department, Cochin Hospital, APHP, PARIS, France, ⁵Rheumatology department, Cochin hospital, Paris, France, ⁶Université Paris Cité, Paris, France
Background/Purpose: The risk of interstitial lung disease is well established in Rheumatoid Arthritis (RA). Less is known about the airway involvement which has been estimated…
Abstract Number: 2248 • ACR Convergence 2025
Elevated Anti-PAD Autoantibodies in a Singaporean Chinese Rheumatoid Arthritis (RA) Cohort with Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) Positivity: A Case-control Exploratory Study
Margaret Ma¹, Khai Pang Leong², ee tzun koh², Preeti Dhanasekaran³, janique peyper⁴, bermet abylova⁴, Anselm Mak³ and Peter Cheung¹, ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³National University of Singapore, Singapore, Singapore, ⁴Standard BioTools, Singapore, Singapore
Background/Purpose: Autoantibody-based biomarkers including ACPA and RF are of established clinical use in rheumatoid arthritis (RA) and are ingrained in international classification criteria. However, other…
Abstract Number: 2230 • ACR Convergence 2025
Racial and Ethnic Disparities in Rheumatoid Arthritis-Associated Interstitial Lung Disease and Their Impact on Antifibrotic Therapy
Andrea Galecio Chao, Baylor College of Medicine, Houston, TX
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a significant cause of morbidity and mortality among patients with rheumatoid arthritis (RA), often leading to progressive…
Abstract Number: 1984 • ACR Convergence 2025
Improving Lipid Screening Rates in Rheumatic Disease Patients: An Academic Fellowship Quality Improvement Project
Mahnoor Javed¹, Deepak Jagannath², Lilly Morgan¹, Rishi Patel¹, Eleonora Avenatti¹, Kanika Monga¹ and Kenneth Williams¹, ¹Houston Methodist, Houston, ²Houston Methodist Hospital, Sugar Land, TX
Background/Purpose: Autoimmune diseases, including rheumatoid arthritis (RA) and spondyloarthritis (SpA)—which encompasses ankylosing spondylitis (AS) and psoriatic arthritis (PsA)—are associated with chronic inflammation and increased cardiovascular…
Abstract Number: 1905 • ACR Convergence 2025
Exploring the Association Between Environmental Quality Index and Rheumatoid Arthritis Mortality in the United States
Rohan Sharma¹, Eric Yen² and Ram Singh³, ¹UCLA, Bakersfield, CA, ²UCLA, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Environmental factors such as smoking, pollutants, diet, and geography as well as sex, race/ethnicity, and genetics have been linked with rheumatoid arthritis (RA) pathogenesis…
Abstract Number: 1738 • ACR Convergence 2025
Coexpression and Infiltration of Endoplasmic Reticulum Stress Proteins Together With CD34+ Fibroblast-like Synoviocytes In Human Inflamed Synovial Membranes
Zoe Gendebien¹, Pauline Salpetier², Celine Deroyer², Genevieve Paulissen², Alexandre Hego², Gaetan Lefevre², Christophe Poulet², Sophie Neuville², Patrick Durez³, Patrice Hemon⁴, Nadege Marec⁵, Elettra Bianchi², Philippe Delvenne², Clio ribbens² and Dominique de Seny², ¹ULiege, Liège, Belgium, ²ULiege, Liege, Belgium, ³Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, ⁴Brest, Brest, Belgium, ⁵Brest, Brest, France
Background/Purpose: A strong crosstalk exists between endoplasmic reticulum (ER) stress and synovitis. Several ER chaperone proteins, besides their function in protein folding, can play a…
Abstract Number: 1659 • ACR Convergence 2025
Prevalence and Progression of Multimorbidity in Rheumatoid Arthritis-Associated Interstitial Lung Disease
James Fagerland¹, Yangyuna Yang¹, Punyasha Roul², Tate Johnson¹, Scott Matson³, Grant Cannon⁴, Brian Sauer⁵, Jeffrey Curtis⁶, Joshua Baker⁷, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, OMAHA, NE, ²UNMC, Omaha, NE, ³University of Kansas, Kansas City, MO, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Multimorbidity, the presence of multiple chronic conditions, is common in RA, and the progression of multimorbidity in RA is associated with poor long-term outcomes.…
Abstract Number: 1368 • ACR Convergence 2025
Thrombocytosis Predicts Response to Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: Data from the Korean KOBIO Registry
Se Hee Kim¹ and kyung-Ann Lee², ¹Kyung Hee University College of Medicine, Seoul, Republic of Korea, ²Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea
Background/Purpose: This study aimed to evaluate the clinical characteristics of thrombocytosis, its relationship with disease activity and joint involvement, and its influence on the effectiveness…
Abstract Number: 1350 • ACR Convergence 2025
Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study
Daniel Zavada¹, Barbora Vala², Adela Navratilova², Veronika Losterova², Lenka Moravcova², Jiri Vencovsky³, Ladislav Šenolt⁴, Karel Pavelka⁵ and Michal Tomcik⁵, ¹Institute of Rheumatology, Prague; Charles University, Third Faculty of Medicine, Hlavné mesto Praha, Czech Republic, ²Institute of Rheumatology, Praha, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) significantly impacts quality of life in multiple domains. This study aimed to evaluate the impact of initial biologic/targeted synthetic disease-modifying anti-rheumatic…
Abstract Number: 1333 • ACR Convergence 2025
Assessment of lipid abnormalities after initiation of a JAK inhibitor in rheumatoid arthritis in clinical practice
Salomé Abdellaoui¹, Omar Al Tabaa¹, Sophie Hecquet¹, Alice Combier¹, Sandrine Carves¹, Olivier Fogel², Yannick Allanore³ and Jérôme Avouac⁴, ¹Rheumatology department, Cochin Hospital, Paris, France, ²AP-HP, Paris, France, ³Université Paris Cité, Paris, France, ⁴Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: rheumatoid arthritis (RA) is characterized by a lipid paradox induced by systemic inflammation. JAK inhibitors (JAKi) have been associated with a short-term increase in…
Abstract Number: 1317 • ACR Convergence 2025
The Association Between Insomnia and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 546,822 Patients
Mohamed Abdelsalam¹, Maryam Lasheen², Menat Alla Ayman Ali Mahdy³, Hadeer Hafez⁴, Nourhan Abouelella⁵, Mohamed Al-Adl⁶ and Mohamed Reda Awad⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁶Faculty of medicine Al-Azhar University Cairo, Nasr City, Egypt, ⁷Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Insomnia and rheumatoid arthritis (RA) are caught in a snowball effect, where chronic pain disrupts sleep and causes poor sleep quality, which in turn…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].